Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl (Nasdaq:CELG) today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52^nd Annual Meeting of the American Society of Hematology comparing REVLIMID^® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

This analysis was conducted to determine the effect on survival in 445 patients with NDMM that were randomized to Rd or RD and then analyzed in two age groups: younger than age 65 and 65 and older.

These results showed a two-year survival rate of 92% (99/108) in the Rd arm of the analysis compared to 86% (88/104) in the RD arm in patients younger than 65. In patients 65 and older, the two year survival rate was 85% (97/114) in the Rd arm vs. 72% (86/119) in the RD arm.

Grade 3 or higher non-haematologic toxicities were reported less frequently in the Rd arm than the RD arm (50.5% vs. 61.4%). Patients aged less than 65 or older than 65 in the Rd arm had less frequent grade 3 or higher non-haematologic toxicities(45.8% and 54.9%, respectively) than patients in the RD arm (52.9% and 68.9% respectively).

These data are from an investigational study. REVLIMID is not approved as an initial treatment for patients with multiple myeloma.